Dose-dependent *in vitro* effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus


ABSTRACT: Recombinant human deoxyribonuclease (rhDNase) has been demonstrated to reduce the viscosity of purulent cystic fibrosis (CF) respiratory mucus, to improve pulmonary function and to reduce the risk of respiratory tract infectious exacerbations, but its effect on mucus transportability has not so far been investigated.

The dose-dependent effect of rhDNase was analysed *in vitro* on mucus transport rate (tr) by ciliary activity and by simulated cough (cough transport (ct)), as well as on mucus viscosity and surface properties. Purulent CF sputa (n=15) were incubated for 30 min at 37°C with either rhDNase at three different concentrations (final concentrations 0.2, 2 or 20 µg·ml⁻¹ of mucus) or placebo.

No significant dose-dependent effect of rhDNase on the mucociliary transport rate was observed when the samples were statistically analysed together. However, in the larger group of mucus samples (n=11) with a low initial mucociliary transport rate, the latter was improved at each rhDNase concentration (tr₀.₂=0.69, tr₂=0.88 and tr₂₀=0.87) as compared to placebo (trₚ=0.58). In the smaller group of mucus samples (n=4) with high initial transport rate, a decrease in mucociliary transport rate was observed, particularly at the highest concentration rhDNase assayed, i.e. 20 µg·ml⁻¹ of mucus (tr₂₀=0.58) as compared to placebo (trₚ=0.86). The mucus cough transport was increased by rhDNase (ct₀.₂=25 mm, ct₂=27.5 mm and ct₂₀=31 mm) as compared to placebo (ctₚ=23.5 mm). The alterations in the mucus transport capacity were associated with a decrease in mucus viscosity and an improvement in mucus surface properties.

These results suggest that rhDNase, at concentrations found in respiratory mucus after inhalation of the recommended therapeutic dose, improves both the cough and mucociliary transport of CF mucus samples characterized by a low mucociliary transport rate.

Eur Respir J., 1995, 8, 381–386.

Cystic fibrosis (CF) is characterized by a general dysfunction of surface airway epithelial cells and of exocrine glands of the respiratory tract, caused by cystic fibrosis transmembrane conductance regulator (CFTR) mutations. The ion and water transport dysfunctions produce dehydrated and highly viscous mucus, which contributes to a decreased mucociliary transport and accumulation of infected secretions [1]. Due to persistent infection, numerous neutrophils release large amounts of deoxyribonucleic acid (DNA) which contribute to the increased viscous properties of the purulent respiratory mucus [2, 3].

It has been reported previously that bovine pancreatic deoxyribonuclease (DNase) reduced the viscosity of lung secretions *in vitro* [4, 5]. However, adverse reactions after the inhalation of bovine pancreatic DNase led to this foreign protein no longer being used [6]. A highly purified recombinant human DNase I (rhDNase) was recently produced, and was found to dramatically reduce the viscosity of CF sputum [7]. Multicentre clinical studies demonstrated the safety and efficacy of the short-term and long-term administration of aerosolized rhDNase on the pulmonary function and symptoms of CF patients [8–10]. However, the dose-dependent effect of rhDNase on mucus transportability is still unknown.

We therefore addressed the question of whether rhDNase could improve *in vitro* mucus transport by ciliary activity and by cough. In association with the transport
measurements we analysed the dose-dependent effect of rhDNase on the rheological and surface properties of mucus.

**Material and methods**

**Study subjects**

Fifteen cystic fibrosis patients were included in this study. The median age of the group of patients was 19 yrs (range 6–25 yrs). Nine patients were homozygous for the ΔF508 mutation and six were heterozygous. Their vital capacity and forced expiratory volume, expressed as percentage of predicted value (% pred), ranged between 45–108% pred (median=74% pred) and 18–101% pred (median=53% pred), respectively. The Shwachman score ranged between 45–90 (median=66). To collect respiratory mucus by expectoration, physiotherapy was performed for 30 min in these patients. Dental cottonwool swabs were placed in the mouth of the patient during expectoration to limit salivary contamination [11]. Twelve of the 15 patients were colonized by *Pseudomonas aeruginosa*. All mucus samples appeared purulent.

**Study design**

After expectoration, each mucus sample was kept at 4°C and analysed within 24 h. For analysis, the mucus sample was divided into four aliquots. Each aliquot was incubated for 30 min at 37°C, either with placebo (NaCl 150 mM + 1 mM CaCl₂ = control), or with three different concentrations of rhDNase (final concentrations 0.2, 2 or 20 µg·ml⁻¹ of mucus). The volume of placebo or rhDNase diluted in placebo which was added to the mucus represented 4% of the mucus sample volume. It was gently stirred into the mucus for 5 s. After the incubation period, we analysed the viscoelastic and surface properties of each mucus aliquot. We also measured the mucus transport by ciliary activity (frog palate model) and by cough (simulated cough machine).

**Methods**

**Viscoelastic properties**

The mucus viscoelastic properties were analysed by using a controlled stress rheometer (Carri-Med) equipped with a cone-plate geometry [12]. The angle between the cone and the plate was 0.017 radian, and the sample volume required was 20 µl. The measurements were carried out at 25°C using the creep test technique. A constant stress of 10 Pa was applied to the sample, and the resultant strain was recorded versus time. When a steady flow was achieved, the applied stress was suppressed and the recovery angle (γ) of the strain, representative of the mucus elasticity, was measured. The slope of the strain versus time curve represented the shear rate applied to the mucus sample. The ratio shear-stress/shear-rate and the ratio shear stress/shear strain allowed us to calculate the mucus viscosity and the mucus elastic modulus, respectively.

**Surface properties**

The mucus surface properties were analysed by measuring the contact angle of a 20 µl drop of mucus, which was deposited on a glass slide in a small chamber with 100% relative humidity. An image analysis technique was used to measure the angle between the tangent to the mucus-air interface and the horizontal at the contact point of the drop of mucus with the glass slide [13].

**Mucus transport by cough**

The experiments were performed using the cough machine developed by King et al. [14]. A tank of 6 l volume was used as reservoir for pressurized air, and was connected through a solenoid valve to a plastic tube simulating the trachea. The floor of this tube was a glass slide, on which the drop of mucus used for contact angle measurement was deposited. A cough was simulated by opening the solenoid valve, releasing the pressurized air through the model trachea in which the airflow was 6 l·s⁻¹. The distance travelled by the mucus under the effect of the airflow was measured, and represented the mucus cough transport. According to the volume of mucus collected, one or two measurements were made for each aliquot.

**Mucus transport by ciliary activity**

*In vitro* measurements of the mucus transport by the ciliary activity were made using the frog palate technique [15]. Isolated palates from frogs (*Rana esculenta*) were placed in a plexiglass chamber at a controlled temperature (25°C) and in 100% relative humidity. After 24h, endogenous mucus secretion of the isolated palate was exhausted but the cilia remained active. This depleted palate was used to measure the mucociliary transport both of the control frog mucus and the CF respiratory mucus. A drop of mucus (1 µl) taken from the palate of a recently killed frog was placed on the depleted palate, and its transport velocity was measured by following the velocity of a calibrated aluminium disc (600 µm in diameter) placed on the mucus drop. Thereafter, the transport velocity of the CF respiratory mucus aliquots was measured in the same manner, and the results were expressed as relative transport rate (tr) corresponding to the ratio of CF respiratory mucus transport rate to the control frog mucus transport rate, both being measured at the same time on the same depleted frog palate. Three measurements were made for each mucus aliquot.
Total DNA content measurement

Mucus DNA content was determined by a modification of the diaminobenzoic acid (DABA) assay [16] developed by Kissane and Robins [17]. Briefly, mucus was diluted tenfold with diluent (hydroxyethylpiperazine ethanesulfonic acid 25 mM (HEPES,) 1 mg·ml⁻¹ bovine serum albumin, (BSA) 4 mM CaCl₂, 0.05% polysorbate 20, and 0.01% thimerasol, pH 7.5) and incubated at 60°C for 1 h.

Fifty microlitres of the diluted mucus were incubated in microtitre plate wells with 50 µl of 20% 3,5-diaminobenzoic acid hydrochloride solution at 60°C for 1 h, and then 50 µl of 5 N HCl was added to stop the reaction. Fluorescence was measured in a microtitre plate fluorometer (with 390 nm excitation and 530 nm emission filters). Salmon testes DNA (Sigma) was used to establish the standard curve. This assay, which measures total DNA concentration independent of its length, was performed on 11 of the 15 samples (the volume was too small for four samples).

Statistical analysis

All the data are expressed as a median value and interquartile range. The Spearman correlation test was used to relate the DNA content to the rheological and surface properties of mucus. The nonparametric Kruskal-Wallis test was used to analyse the dose-dependent effect of rhDNase on the rheological and functional properties of mucus. The nonparametric Wilcoxon test was used to compare the control mucus with the DNase-treated mucus. A p-value of less than 0.05 was considered as significant.

Results

The DNA content in the sputum samples ranged 2.4–19.5 mg·ml⁻¹ (median 8.5 mg·ml⁻¹) and was significantly correlated to the viscosity and the elastic modulus of the mucus (fig. 1): the higher the DNA content, the higher the viscosity (r=0.82; p<0.002) and the higher the elastic modulus (r=0.84; p<0.002) of the respiratory mucus.

Compared to control, a significant decrease in the mucus viscosity was observed when the samples were incubated with rhDNase. Nevertheless, no significant difference was obtained between the effect of each concentration of rhDNase (fig. 2a). The decrease in mucus viscosity observed at each rhDNase concentration was significantly correlated to the initial mucus DNA content (r=0.85; p<0.01): the higher the DNA content, the larger the decrease in mucus viscosity. No significant dose-dependent effect of rhDNase was observed on the mucus elastic modulus. However, for each rhDNase concentration the mucus contact angle was significantly decreased as compared to control (fig. 2b).

The mucus cough transport was significantly improved in a dose-dependent way when incubated in the presence of the different concentrations of rhDNase (fig. 3a). Compared to control (23.5 mm), incubation with...
rhDNase at a concentration of 2 and 20 µg·ml⁻¹ of mucus led to a significant (p<0.05 and p<0.01, respectively) increase in mucus cough transport (27.5 and 31.0 mm, respectively). The incubation with rhDNase at a concentration of 2 or 20 µg·ml⁻¹ of mucus significantly increased the mucus cough transport as compared to the mucus cough transport observed with rhDNase at 0.2 µg·ml⁻¹ of mucus (p<0.05 and p<0.0007, respectively). In addition, rhDNase at 20 µg·ml⁻¹ of mucus significantly increased the cough transport as compared to rhDNase at 2 µg·ml⁻¹ of mucus (p<0.0009).

No significant improvement in mucus transport by ciliary activity was observed in response to rhDNase when the mucus transport rates were analysed as a whole (fig. 3b). However, when we plotted the percentage change of mucociliary transport rate measured before and after incubating the mucus samples with the different rhDNase concentrations versus the initial mucociliary transport rate, we observed that the response to rhDNase was apparently related to the initial mucus transport rate (fig. 4). In fact, two groups could be identified: 1) one larger group of mucus samples (n=11) characterized by an initial mucociliary transport rate ranging 0.4–0.7, which were always improved by the rhDNase; and 2) another smaller group of mucus samples (n=4) characterized by an initial mucociliary transport rate higher than 0.8, in which higher rhDNase concentrations, >2 µg·ml⁻¹ of mucus, always depressed transport rate. In these, a low concentration of rhDNase (0.2 µg·ml⁻¹ of mucus) sometimes accelerated transport rate.

In both groups, a significant dose-dependent effect of rhDNase was observed. The mucociliary transport rate was significantly improved (p<0.001) in the larger group of patients with a low initial mucociliary transport rate, whereas it was significantly (p<0.05) decreased in the smaller group of patients with a high initial mucociliary transport rate. It is noteworthy that the percentage change of the mucociliary transport rate after incubation with 2 or 20 µg of rhDNase per ml of mucus was significantly (p<0.01) and negatively correlated (r=-0.69 and r=-0.63, respectively) with the initial mucociliary transport rate: the higher the initial mucociliary transport rate, the lower the increase after rhDNase treatment. This difference in response to rhDNase could not be related to the DNA content or to the viscosity of the native mucus, which were not significantly different in the two groups of patients.

Discussion

The present study demonstrates that rhDNase significantly decreased the CF respiratory mucus viscosity in vitro in a dose-dependent way. In association with the viscosity decrease, a significant improvement in the mucus transport by the cough was observed. The improvement by rhDNase of mucus transport by ciliary activity was only evident when the mucus samples were characterized by a depressed initial transport rate.

Large amounts of DNA (2.4–19.5 mg·ml⁻¹) were present in the mucus samples analysed in our study, and were in the range of the amounts reported in previous
We have shown that the increase in mucus DNA content is associated with an increase in mucus viscosity and mucus elastic modulus. This increase in mucus rheological properties may be related to the high molecular weight of DNA. However, other biochemical factors, such as proteins, glycoproteins and lipids, are involved in the control of the rheological properties of CF mucus [18]. In addition, it has recently been reported that filamentous actin is contained in CF mucus and might also contribute to its thickness [19].

We analysed the effect of rhDNase on the mucus surface properties by measuring the mucus contact angle. We observed that rhDNase induced a significant decrease in the mucus contact angle, which reflects a decrease in mucus surface tension. A decrease in the surface tension of mucus is generally associated with a decrease in the adhesive properties of the mucus and a parallel increase in the transport capacity by ciliary activity and by cough [20]. The improvement in the mucus surface properties cannot be explained by a direct effect of the rhDNase surface tension, since the surface tension of rhDNase was similar to the surface tension of the control solution (data not shown). Two mechanisms could be involved in the decrease in mucus surface properties due to DNA fragmentation by rhDNase: 1) a direct alteration of the mucus surface properties induced by smaller DNA molecules; and 2) a recovery of surface active molecules, such as lipids, which might be dissociated from DNA [21]. Surface active molecules, such as phospholipids, play an important role in mucus adhesive properties [20].

The increase in CF respiratory mucus viscosity is frequently associated with decreased cough transport and decreased ciliary transport [20]. The effectiveness of the cough transport is strongly dependent on the mucus viscosity and on the mucus surface properties: low viscous and adhesive properties promote mucus transport by cough [22]. A decrease in the mucus viscosity and in the mucus contact angle by rhDNase is associated with a significant dose-dependent increase in mucus transport by cough: the higher the rhDNase concentration, the more efficient the mucus transport by cough. Thus, these in vitro results suggest that rhDNase may improve cough clearance. However, the effect of rhDNase on mucus transport by ciliary activity appears to vary according to the rhDNase concentration and the initial mucus transport rate. Our results demonstrate that mucus samples with an abnormally low initial mucociliary transport capacity (in the range 0.4–0.7) were always improved when incubated with rhDNase, which is the case for 75% of the CF patients involved in this study. Mucus samples having an initial mucociliary transport capacity higher than 0.8 show impairment in their mucociliary transport capacity after being incubated with a high rhDNase concentration (up to 20 µg·ml⁻¹ of rhDNase per ml of mucus). It is noteworthy that only one mucus sample out of 15 had a depressed mucociliary transport rate when incubated with rhDNase at 0.2 µg·ml⁻¹ of mucus. This impairment may be explained by an excessive decrease in mucus viscosity, which induces a decrease in mucus transport by ciliary activity. We have previously considered that a mucociliary transport rate higher than 0.7 can be considered as normal [15], which corresponds in the present work to the limit value for which the response of mucociliary transport rate to rhDNase becomes negative.

It is widely acknowledged that there is no simple linear relationship between respiratory mucus viscosity and mucociliary transport rate. In fact, respiratory mucus might be characterized by an optimal range of viscosity for optimal mucociliary transport [23]. A very high viscosity of mucus decreases the ciliary beating frequency, whereas mucus with low viscosity induces a decrease in the mucus transport rate without any alteration of the ciliary beating frequency. However, in addition to the improvement in the viscosity and/or surface properties of mucus, a direct effect of rhDNase on the ciliary beating frequency could also explain the improvement in the mucociliary transport rate. This hypothesis should be further investigated.

Clinical studies on administration of aerosolized rhDNase in patients with cystic fibrosis have been undertaken using doses up to 10 mg three times a day [8–10]. The mean value of rhDNase concentrations in the respiratory mucus 15 min after aerosolization of the recommended therapeutic 2.5 mg dose has been reported to be 2.9 µg·ml⁻¹ of mucus [24] and it is, therefore, in the range of the concentrations that have been shown to be efficient in the present study. An improvement in mucus clearability due to this enzyme therapy could explain the improvement in the pulmonary function, the reduction in infectious exacerbations, and the perception of well-being in treated cystic fibrosis patients [8].

References
5. Chemick WS, Barbero GJ, Eichel HJ. *In vitro evaluation*


